A single‐ and multiple‐ascending dose study to evaluate the safety and pharmacokinetics of oral PU‐AD, an epichaperome inhibitor to treat Alzheimer's disease: Human/Trial design.

Autor: Silverman, Michael, Wallner, Barbara, Key, Cassandra, Duggan, Susan M., Reynolds, Laurie

Publikováno v: Alzheimer's & Dementia: The Journal of the Alzheimer's Association; Dec2020 Supplement S11, Vol. 16 Issue 11, p1-1, 1p